Mode
Text Size
Log in / Sign up
N/A N=514 Randomized Treatment

Bilateral Transversus Abdominis Plane Block With Exparel Verus Continuous Epidural Analgesia With Bupivacaine

Pain, Postoperative · Major Abdominal Surgery

Enrolled (actual)
514
Serious AEs
0.0%
Results posted
Jan 2024
Primary outcome: Primary: VRS Pain Score — 4.3; 4.2 score on a scale — p=<0.001

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
TAP block (Procedure); Epidural analgesia (Procedure); EXPAREL (Drug); Bupivacaine (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
The Cleveland Clinic
Primary completion
Jun 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
VRS Pain Score
4.3; 4.2 <0.001 sig
PRIMARY
Total Opioid Consumption
56; 35 0.754
SECONDARY
Cumulative Duration of Activity
1.1; 1.0 0.560
SECONDARY
Opioid-related Side Effect
5.8; 5.5; 4.9; 4.5; 3.8; 3.7 0.357
SECONDARY
Hemodynamic Instability, Defined as Mean Arterial Pressure (MAP) <55 mmHg or Systolic Blood Pressure <80 mmHg.
41; 57 0.006 sig
SECONDARY
Quality of Recovery After Anesthesia
102; 100; 111; 111 0.695
SECONDARY
Length of Hospital Stay
4.0; 4.0 0.738

Summary

Comparison of Bilateral Transversus Abdominis Plane Block with Exparel versus Continuous Epidural Analgesia With Bupivacaine

Eligibility Criteria

Inclusion Criteria

  • Written informed consent
  • 18-85 years old
  • ASA Physical Status 1-3
  • Scheduled for elective open or laparoscopic abdominal surgery, including colorectal and hysterectomy surgeries
  • Anticipated hospitalization of three nights
  • Expected requirement for parenteral opioids for at least 72 hours for postoperative pain
  • Able to use IV PCA systems.

Exclusion Criteria

  • Hepatic disease, e.g. twice the normal levels of liver enzymes
  • Kidney disease, e.g. twice the normal level of serum creatinine
  • Bupivacaine sensitivity or known allergy
  • Women who are pregnant or breastfeeding
  • Anticoagulants considered to be a contraindication for epidural or TAP blocks.
  • Surgeries with high port sites will be excluded
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02996227). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search